Medexus Pharmaceuticals Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Medexus Pharmaceuticals Inc. is a leading specialty pharmaceutical company focused on the acquisition, development, and commercialization of innovative treatments in hematology-oncology, allergy, dermatology, rheumatology, and auto-immune diseases across North America. Founded in 2003 and headquartered in Toronto, Ontario, Canada, with key operations in Chicago, Illinois, the company markets a diverse portfolio of prescription and over-the-counter products including IXINITY, an intravenous recombinant factor IX therapeutic for hemophilia B; Rasuvo and Metoject, unique auto-injector and pre-filled syringe formulations of methotrexate for rheumatoid arthritis and other auto-immune conditions; Rupall, an innovative allergy medication; Gleolan, an optical imaging agent for glioma surgery; GRAFAPEX and Trecondyv, bifunctional alkylating agents used in conditioning for allogeneic hematopoietic stem cell transplantation; Cuvposa, a glycopyrrolate oral solution; as well as Naproxen suspension, Otixal, Trispan, Nyda for head lice, Relaxa laxative, Oralvisc for osteoarthritis, and Calcia calcium-vitamin D supplements; primarily to wholesalers, distributors, healthcare facilities, specialty pharmacies, and government agencies in Canada and the United States. In November 2025, Medexus announced US$51.0 million in new credit facilities to support growth initiatives and its intention to commence a normal course issuer bid for common shares.
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Medexus Pharmaceuticals Inc. (MDP:CA) Q3 2026 Earnings Call Transcript
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Medexus Pharmaceuticals Inc. (MDP:CA) Q2 2026 Earnings Call Transcript
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Medexus Pharmaceuticals Inc. (MDP:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Medexus Pharmaceuticals Inc. (MEDXF) Q1 2026 Earnings Call Transcript
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Medexus Schedules First Fiscal Quarter 2026 Conference Call
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026
Medexus Pharmaceuticals Inc. (MEDXF) Q4 2025 Earnings Call Transcript
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States